Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973367 | 0.86 | OPRM1 (0.58) | OPRM1KCNH2TMEM97 | |
| SCHEMBL2969726 | 0.85 | OPRM1 (0.57) | OPRM1TMEM97 | |
| SCHEMBL2979356 | 0.80 | OPRM1 (0.52) | OPRM1TMEM97 | |
| SCHEMBL2975704 | 0.80 | C5AR1 (0.59) | OPRM1KCNH2TMEM97DCUN1D1 | |
| SCHEMBL2980152 | 0.78 | C5AR1 (0.62) | OPRM1CCR5 | |
| SCHEMBL2979192 | 0.76 | DCUN1D1 (0.59) | OPRM1DCUN1D1 | |
| SCHEMBL2973375 | 0.75 | CHRM2 (0.53) | OPRM1 | |
| SCHEMBL2970172 | 0.75 | HRH3 (0.43) | OPRM1 | |
| SCHEMBL3587044 | 0.75 | KCNH2 (0.60) | OPRM1KCNJ1KCNH2 | |
| SCHEMBL2967235 | 0.74 | OPRM1 (0.48) | OPRM1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | OPRM1 627/4885CCR5 1462/4885KCNJ1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.